Understanding youth cannabis treatment in Alberta
Summary
The study wants to understand youth perspectives and experiences of cannabis use treatment. The study consists of taking part in an interview. We want to hear from youth (16-24), parents or legal guardians of youth, and clinicians or treatment providers.
We want to understand how, when, and where youth and their families access cannabis treatment, or if they wanted treatment or could not access it.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 16 to 65
Accepts healthy participants: Yes
Inclusion criteria:
You can participate in this study if:
1. You live in Alberta.
2. You are a young person between the ages 16-24 and have previously received (in the last four years) or are currently seeking cannabis use treatment.
3. You are a Parent or caregiver of youth ages 16-24 and have previously received (in the last four years) or are currently seeking cannabis use treatment.
4 . You are a clinician or professional who was previously or is currently working in mental health, substance use, youth justice, child welfare, and education sectors in Alberta at some point over the past fours years.
Exclusion criteria:
You are not eligible to participate if:
1. You are under the age of 16 or over the age of 24.
2. You don't have any experience with receiving or seeking cannabis use treatment in Alberta as a youth or parent/caregiver.
3. You/your child accessed treatment more than four years ago.
4. You/your child's treatment did not take place in Alberta.
5. Your clinical experience with cannabis greater than four years ago or did not take place in Alberta.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Dr. Rebecca Saah
Principal investigator:
Rebecca Saah
Clinical trial:
No
REB-ID:
REB23-0147